AML cells respond to GO-203 with induction of ROS-mediated myeloid differentiation. (A) MOLM-14 cells were left untreated (□), and treated with 2.5μM GO-203 (■) or 2.5μM CP-2 (▩) each day for the indicated days. Cells were analyzed for the percentage with expression of CD11b (left) and CD11c (right). (B) MOLM-14 cells were left untreated, and treated with 2.5μM GO-203 or 2.5μM CP-2 each day for 6 days. Lysates were immunoblotted with the indicated antibodies (left). Cells were seeded in agar in the absence of drug and colonies were counted at 14 days. The results are expressed as the number of colonies (mean ± SD of 3 determinations) (right). (C) AML patient 1 cells were left untreated (□), and treated with 2.5μM GO-203 (■) or 2.5μM CP-2 (▩) each day for the indicated days. Cells were analyzed for the percentage with expression of CD11c (left). On day 6, the cells were seeded in agar in the absence of drug and colonies were counted at 14 days. The results are expressed as the number of colonies (mean ± SD of 3 determinations) (right). (D) MOLM-14 (left) and MV4-11 (right) cells were treated with 2.5μM GO-203 in the absence (□) and presence (■) of 5mM NAC for 6 days. The cells were then analyzed for the percentage with expression of CD11b and CD11c.